Drug survival of IL-23 and IL-17 inhibitors versus other biologics for psoriasis: A British Association of Dermatologists Biologics and Immunomodulators Register cohort study.

ABSTRACT:

Background

Interleukin (IL)-23p19 and IL-17 inhibitors have demonstrated high efficacy for psoriasis in randomized controlled trials, though real-world data, particularly for risankizumab (IL-23p19 inhibitor) and brodalumab (IL-17 receptor (IL-17R) inhibitor), is limited.

Objectives

To assess drug survival of IL-23p19 and IL-17 inhibitors compared to other biologics for psoriasis.

Methods

We conducted a cohort study using data from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR) from November 2007 to June 2023. Multivariable flexible parametric models assessed drug survival, with discontinuation due to ineffectiveness and adverse effects reported separately. The primary outcome measure was the absolute difference in restricte

SUBMITTER: Motedayen Aval L 

PROVIDER: S-EPMC12466084 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature